Sign In
Free Newsletter
NJ pharma drugs among 15 targeted in Medicare price talks (updated)
CMS targets 15 high-spend drugs for Medicare price negotiations, including therapies from New Jersey-based Novartis, Johnson & Johnson and Bristol Myers Squibb.
Appeals court rejects NJ pharma challenges to Medicare drug pricing (updated)
New Jersey giants, including J&J, BMS and Novartis, have all lost challenges to the Inflation Reduction Act program, setting up the U.S. Supreme Court as the last lever remaining for potential relief.
Wegovy, Ozempic targeted for Medicare price negotiations (updated)
The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the second round of the program Jan. 17.
Novo Nordisk expects Ozempic in next round of Medicare price talks
In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D for the first cycle of negotiations.
Judge rejects J&J, BMS challenges to Medicare drug pricing program
“Selling to Medicare is a choice plaintiffs can accept or not accept," wrote Judge Zahid Quraishi. "[It] may be less profitable than it was before the institution of the program, but that does not make the defendants’ decision to participate any less voluntary.”
NJ drugmakers’ products among first targeted for Medicare price negotiations
Pharmaceutical companies, including Merck, Johnson & Johnson and others, are concerned the move will hamper innovation and impede patient access and choice.
